Clinical Trials Browser

Neoplasm Metastasis

Carcinoma, Hepatocellular

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung

Advanced Solid Tumor

Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Advanced Non-Small Cell Lung Cancer

Endometrial Neoplasms

Carcinoma, Hepatocellular

Advanced Solid Tumours

Carcinoma, Non-Small-Cell Lung

Advanced Solid Tumors

Advanced Cervical Cancer

Non-Squamous Non-Small Cell Lung Cancer

Carcinoma, Hepatocellular

Advanced Lung Cancer

Advanced Lung Cancer

Advanced Biliary Tract Cancer

Stomach Neoplasms

Carcinoma, Non-Small-Cell Lung

Advanced Solid Tumors

Squamous NSCLC

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Advanced Solid Tumor

Adenocarcinoma of Lung, Osteosarcoma

Carcinoma, Hepatocellular

Lymphoma, Large B-Cell, Diffuse

Advanced or Metastatic Solid Tumors

Advanced/Metastatic Solid Malignancies

Esophageal Squamous Cell Carcinoma

Carcinoma, Hepatocellular

Clinical Trials

Study of ABO2102 in KRAS-Mutated Solid Tumors

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

IBI188 Combination Therapy in Solid Tumors

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.